ImmunityBio, Inc./ "A Multiceter Clinical Trial of ntravesical Bacillus Calmette-Guerin (BCG) in Combination with BCG Unresponsice High Grade Non-Muscle Invasive Bladder Cancer

You are being asked to participate in this research study because you have been diagnosed with a type of non-muscle invasive bladder cancer (NMIBC) and when you were previously treated with Bacillus Calmette-Guerin (BCG), a standard therapy for NMIBC, you had a limited or no response to the treatment (BCG unresponsive). This means that your disease either did not improve on treatment or progressed following at least one course of treatment with BCG, or it returned within 12 months after receiving at least two courses of BCG treatment. The current standard of care for BCG unresponsive bladder cancer is for the surgeon to offer removal of your bladder (cystectomy), which may reduce the risk of your disease progressing to invasion of the muscle layer of your bladder but may be associated with complications, morbidity and decreased quality of life.